P21 mediates macrophage reprogramming through regulation of p50-p50 NF-κB and IFN-β

Journal of Clinical Investigation

Volumn 126, Issue 8, 2016, Pages 3089-3103

  Rackov, Gorjana ^a   Hernández Jiménez, Enrique ^b   Shokri, Rahman ^a   Carmona Rodríguez, Lorena ^a   Mañes, Santos ^a   Álvarez Mon, Melchor ^c   López Collazo, Eduardo ^b   Martínez A, Carlos ^a   Balomenos, Dimitrios ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CD11B ANTIGEN; CD19 ANTIGEN; CD40 ANTIGEN; CD69 ANTIGEN; CXCL11 CHEMOKINE; CYCLIN DEPENDENT KINASE 2; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GAMMA INTERFERON; GLYCOPROTEIN P 15095; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON REGULATORY FACTOR 3; MACROPHAGE DERIVED CHEMOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN P21; PROTEIN P50; STAT1 PROTEIN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYTOKINE; LIPOPOLYSACCHARIDE; PROTEIN BINDING; RELA PROTEIN, HUMAN; TRANSCRIPTION FACTOR RELA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PLASTICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA BINDING; DNA PROTEIN COMPLEX; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MONOCYTE; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PERITONEUM MACROPHAGE; POLARIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SEPSIS; UBIQUITINATION; UPREGULATION; AGED; ANIMAL; GENE EXPRESSION REGULATION; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; METABOLISM; MIDDLE AGED; PHENOTYPE; PROTEIN MULTIMERIZATION; TRANSGENIC MOUSE;

AGED; ANIMALS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERFERON-BETA; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, TRANSGENIC; MIDDLE AGED; MONOCYTES; NF-KAPPA B P50 SUBUNIT; PHENOTYPE; PROTEIN BINDING; PROTEIN MULTIMERIZATION; SEPSIS; TRANSCRIPTION FACTOR RELA;

EID: 84987780117     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI83404     Document Type: Article

References (87)

1. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5(12):953-964.
2. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol. 2011;11(11):750-761.
3. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8(12):958-969.
4. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889-896.
5. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32(5):593-604.
6. Mills C. M1 and M2 macrophages: oracles of health and disease. Crit Rev Immunol. 2012;32(06):463-488.
7. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677-686.
8. Edwards JP, Zhang X, Frauwirth KA, Mosser DM. Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol. 2006;80(6):1298-1307.
9. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787-795.
10. Satoh T, et al. Critical role of Trib1 in differentiation of tissue-resident M2-like macrophages. Nature. 2013;495(7442):524-528.
11. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549-555.
12. Porta C, et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci U S A. 2009;106(35):14978-14983.
13. Pena OM, Pistolic J, Raj D, Fjell CD, Hancock RE. Endotoxin tolerance represents a distinctive state of alternative polarization (M2) in human mononuclear cells. J Immunol. 2011;186(12):7243-7254.
14. Foster SL, Hargreaves DC, Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature. 2007;447(7147):972-978.
15. Piao W, et al. Endotoxin tolerance dysregulates MyD88-and Toll/IL-1R domain-containing adapter inducing IFN-beta-dependent pathways and increases expression of negative regulators of TLR signaling. J Leukoc Biol. 2009;86(4):863-875.
16. Cubillos-Zapata C, et al. NFκB2/p100 is a key factor for endotoxin tolerance in human monocytes: a demonstration using primary human monocytes from patients with sepsis. J Immunol. 2014;193(8):4195-4202.
17. Cavaillon JM, Adib-Conquy M. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care. 2006;10(5):233.
18. Pena OM, et al. An endotoxin tolerance signature predicts sepsis and organ dysfunction at initial clinical presentation. EBioMedicine. 2014;1(1):64-71.
19. Shalova IN, et al. Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1α. Immunity. 2015;42(3):484-498.
20. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840-851.
21. Escoll P, et al. Rapid up-regulation of IRAK-M expression following a second endotoxin challenge in human monocytes and in monocytes isolated from septic patients. Biochem Biophys Res Commun. 2003;311(2):465-472.
22. Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 2009;30(10):475-487.
23. Lopez-Collazo E, del Fresno C. Pathophysiology of endotoxin tolerance: mechanisms and clinical consequences. Crit Care. 2013;17(6):242.
24. Ariga SK, et al. Endotoxin tolerance drives neutrophil to infectious site. Shock. 2014;42(2):168-173.
25. Berg DJ, et al. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest. 1995;96(5):2339-2347.
26. Wysocka M, et al. IL-12 suppression during experimental endotoxin tolerance: dendritic cell loss and macrophage hyporesponsiveness. J Immunol. 2001;166(12):7504-7513.
27. Kobayashi K, Hernandez LD, Galan JE, Janeway CA, Medzhitov R, Flavell RA. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell. 2002;110(2):191-202.
28. Sly LM, Rauh MJ, Kalesnikoff J, Song CH, Krystal G. LPS-induced upregulation of SHIP is essential for endotoxin tolerance. Immunity. 2004;21(2):227-239.
29. Xiong Y, Medvedev AE. Induction of endotoxin tolerance in vivo inhibits activation of IRAK4 and increases negative regulators IRAK-M, SHIP-1, and A20. J Leukoc Biol. 2011;90(6):1141-1148.
30. Ziegler-Heitbrock L. The p50-homodimer mechanism in tolerance to LPS. J Endotoxin Res. 2001;7(3):219-222.
31. Adib-Conquy M, et al. NF-κB expression in mononuclear cells of patients with sepsis resembles that observed in lipopolysaccharide tolerance. Am J Respir Crit Care Med. 2000;162(5):1877-1883.
32. Carmody RJ, Chen YH. Nuclear factor-κB: activation and regulation during Toll-like receptor signaling. Cell Mol Immunol. 2007;4(1):31-41.
33. Hayden MS, Ghosh S. Shared principles in NF-κB signaling. Cell. 2008;132(3):344-362.
34. Biswas SK, Tergaonkar V. Myeloid differentiation factor 88-independent Toll-like receptor pathway: sustaining inflammation or promoting tolerance? Int J Biochem Cell Biol. 2007;39(9):1582-1592.
35. Toshchakov V, et al. TLR4, but not TLR2, mediates IFN-β-induced STAT1α/β-dependent gene expression in macrophages. Nat Immunol. 2002;3(4):392-398.
36. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499-511.
37. Dejager L, et al. Pharmacological inhibition of type I interferon signaling protects mice against lethal sepsis. J Infect Dis. 2014;209(6):960-970.
38. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75(4):805-816.
39. Balomenos D, et al. The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development. Nat Med. 2000;6(2):171-176.
40. Salvador JM, et al. Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome. Immunity. 2002;16(4):499-508.
41. Zhu B, et al. Early growth response gene 2 (Egr-2) controls the self-tolerance of T cells and prevents the development of lupuslike autoimmune disease. J Exp Med. 2008;205(10):2295-2307.
42. Chen H, et al. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest. 2011;121(4):1549-1560.
43. Lloberas J, Celada A. p21(waf1/CIP1), a CDK inhibitor and a negative feedback system that controls macrophage activation. Eur J Immunol. 2009;39(3):691-694.
44. Arias CF, et al. p21CIP1/WAF1 controls proliferation of activated/memory T cells and affects homeostasis and memory T cell responses. J Immunol. 2007;178(4):2296-2306.
45. Daszkiewicz L, et al. Distinct p21 requirements for regulating normal and self-reactive T cells through IFN-γ production. Sci Rep. 2015;5:7691.
46. Trakala M, et al. Regulation of macrophage activation and septic shock susceptibility via p21(WAF1/CIP1). Eur J Immunol. 2009;39(3):810-819.
47. Scatizzi JC, et al. The CDK domain of p21 is a suppressor of IL-1β-mediated inflammation in activated macrophages. Eur J Immunol. 2009;39(3):820-825.
48. Mavers M, et al. Cyclin-dependent kinase inhibitor p21, via its C-terminal domain, is essential for resolution of murine inflammatory arthritis. Arthritis Rheum. 2012;64(1):141-152.
49. Ghosn EE, et al. Two physically, function-ally, and developmentally distinct peritoneal macrophage subsets. Proc Natl Acad Sci U S A. 2010;107(6):2568-2573.
50. Ni Gabhann J, et al. Btk regulates macrophage polarization in response to lipopolysaccharide. PLoS One. 2014;9(1):e85834.
51. Singh P, et al. DUSP3 Genetic deletion confers M2-like macrophage-dependent tolerance to septic shock. J Immunol. 2015;194(10):4951-4962.
52. Groeneveld PH, Claassen E, Kuper CF, Van Rooijen N. The role of macrophages in LPSinduced lethality and tissue injury. Immunology. 1988;63(3):521-527.
53. Trinchieri G. Type I interferon: friend or foe? J Exp Med. 2010;207(10):2053-2063.
54. Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol. 2015;15(8):471-485.
55. Nakano H, Yanagita M, Gunn MD. CD11c(+) B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med. 2001;194(8):1171-1178.
56. McDunn JE, et al. Splenic CD4+ T cells have a distinct transcriptional response six hours after the onset of sepsis. J Am Coll Surg. 2006;203(3):365-375.
57. de Pablo R, Monserrat J, Prieto A, Alvarez-Mon M. Role of circulating lymphocytes in patients with sepsis. Biomed Res Int. 2014;2014:671087.
58. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003;101(10):3765-3777.
59. Lush CW, Cepinskas G, Kvietys PR. LPS tolerance in human endothelial cells: reduced PMN adhesion, E-selectin expression, and NF-κB mobilization. Am J Physiol Heart Circ Physiol. 2000;278(3):H853-H861.
60. Biswas SK, et al. Role for MyD88-independent, TRIF pathway in lipid A/TLR4-induced endotoxin tolerance. J Immunol. 2007;179(6):4083-4092.
61. Kawai T, Akira S. Signaling to NF-κB by Toll-like receptors. Trends Mol Med. 2007;13(11):460-469.
62. Garoufalis E, et al. Viral induction of the human β interferon promoter: modulation of transcription by NF-κB/rel proteins and interferon regulatory factors. J Virol. 1994;68(8):4707-4715.
63. Frankenberger M, Ziegler-Heitbrock HW. LPS tolerance in monocytes/macrophages: three 3′ cytosins are required in the DNA binding motif for detection of upregulated NF-κB p50 homodimers. Immunobiology. 1997;198(1-3):81-90.
64. Carmody RJ, Ruan Q, Palmer S, Hilliard B, Chen YH. Negative regulation of Toll-like receptor signaling by NF-κB p50 ubiquitination blockade. Science 2007;317(5838):675-678.
65. Guan H, Hou S, Ricciardi RP. DNA binding of repressor nuclear factor-κB p50/p50 depends on phosphorylation of Ser 337 by the protein kinase A catalytic subunit. Biochemistry. 2005;280(11):9957-9962.
66. Faas MM, et al. Monocyte intracellular cytokine production during human endotoxaemia with or without a second in vitro LPS challenge: effect of RWJ-67657, a p38 MAP-kinase inhibitor, on LPS-hyporesponsiveness. Clin Exp Immunol. 2002;127(2):337-343.
67. Fernandez-Ruiz I, et al. Mitochondrial DAMPs induce endotoxin tolerance in human monocytes: an observation in patients with myocardial infarction. PLoS One. 2014;9(5):e95073.
68. del Fresno C, et al. Monocytes from cystic fibrosis patients are locked in an LPS tolerance state: down-regulation of TREM-1 as putative underlying mechanism. PLoS One. 2008;3(7):e2667.
69. Merched AJ, Chan L. Absence of p21Waf1/ Cip1/Sdi1 modulates macrophage differentiation and inflammatory response and protects against atherosclerosis. Circulation. 2004;110(25):3830-3841.
70. Rajaiah R, Perkins DJ, Polumuri SK, Zhao A, Keegan AD, Vogel SN. Dissociation of endotoxin tolerance and differentiation of alternatively activated macrophages. J Immunol. 2013;190(9):4763-4772.
71. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of Toll-like receptor-mediated immune responses. Nat Rev Immunol. 2005;5(6):446-458.
72. Del Fresno C, et al. Potent phagocytic activity with impaired antigen presentation identifying lipopolysaccharide-tolerant human monocytes: demonstration in isolated monocytes from cystic fibrosis patients. J Immunol. 2009;182(10):6494-6507.
73. van 't Veer C, et al. Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J Immunol. 2007;179(10):7110-7120.
74. Seok J, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2013;110(9):3507-3512.
75. McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15(2):87-103.
76. Yoo CH, Yeom JH, Heo JJ, Song EK, Lee SI, Han MK. Interferon β protects against lethal endotoxic and septic shock through SIRT1 upregulation. Sci Rep. 2014;4:4220.
77. Karaghiosoff M, et al. Central role for type I interferons and Tyk2 in lipopolysaccharideinduced endotoxin shock. Nat Immunol. 2003;4(5):471-477.
78. Huys L, et al. Type I interferon drives tumor necrosis factor-induced lethal shock. J Exp Med. 2009;206(9):1873-1882.
79. Mahieu T, et al. The wild-derived inbred mouse strain SPRET/Ei is resistant to LPS and defective in IFN-β production. Proc Natl Acad Sci U S A. 2006;103(7):2292-2297.
80. Mahieu T, Libert C. Should we inhibit type I interferons in sepsis? Infect Immun. 2007;75(1):22-29.
81. Bohuslav J, et al. Regulation of an essential innate immune response by the p50 subunit of NF-κB. J Clin Invest. 1998;102(9):1645-1652.
82. Wessells J, et al. BCL-3 and NF-κB p50 attenuate lipopolysaccharide-induced inflammatory responses in macrophages. J Biol Chem. 2004;279(48):49995-50003.
83. Kuwata H, et al. IL-10-inducible Bcl-3 negatively regulates LPS-induced TNF-α production in macrophages. Blood. 2003;102(12):4123-4129.
84. Rousselle A, et al. CXCL5 limits macrophage foam cell formation in atherosclerosis. J Clin Invest. 2013;123(3):1343-1347.
85. Mantovani A, Garlanda C, Locati M. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol. 2009;29(10):1419-1423.
86. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013;13(10):709-721.
87. [No authors listed]. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20(6):864-874.